A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Trial Profile

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Alprazolam (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms StATES
  • Sponsors Engage Therapeutics
  • Most Recent Events

    • 20 Mar 2018 Status changed from planning to recruiting.
    • 04 Oct 2017 New trial record
    • 27 Sep 2017 According to an Engage Therapeutics media release, Dr. Jacqueline A. French from the NYU Langone Medical Center, will be the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top